UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D. C. 20549
____________
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act Of 1934
September
16, 2005
Date
of
Report (Date of earliest event reported)
___________________________________________________________
ACURA
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
___________________________________________________________
State
of New York
|
1-10113
|
11-0853640
|
(State
of Other Jurisdiction
|
(Commission
File Number)
|
(I.R.S.
Employer
|
of
Incorporation)
|
|
Identification
Number)
|
616
N. North Court, Suite 120
Palatine,
Illinois 60067
(Address
of principal executive offices) (Zip Code)
(847)
705-7709
(Registrant’s
telephone number, including are code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
› Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
› Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR
240.14a-12)
› Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17CFR240.14d-2(b))
› Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR
240.13e- 4(c))
Item
8.01 Other
Events
On
September 16, 2005, Acura Pharmaceuticals, Inc. (the "Company") issued a press
release announcing completion of bridge financing in the principal amount of
$500,000 pursuant to the terms of that certain Loan Agreement by and among
the
Company and Essex
Woodlands Health Venture V, L.P., Care Capital Investments II, L.P., Care
Capital Offshore Investments II, L.P., Galen Partners III, L.P., Galen Partners
International III, L.P., and Galen Employee Fund III, L.P.,
dated
September 16, 2005. A copy of the Company's press release is attached as Exhibit
99.1 hereto.
Item
9.01 Financial
Statements and Exhibits.
Exhibit
Number
|
Description |
99.1
|
Press
Release dated September 16, 2005 Announcing Completion of $500,000
Bridge
Financing.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
|
|
|
ACURA
PHARMACEUTICALS, INC. |
|
|
|
|
By: |
/s/ Peter A. Clemens |
|
Peter A. Clemens |
|
Vice
President & Chief Financial Officer |
Date: September
16, 2005
EXHIBIT
INDEX
Exhibit
Number
|
Description |
99.1
|
Press
Release dated September 16, 2005 Announcing Completion of $500,000
Bridge
Financing.
|